NCT03226327View on ClinicalTrials.gov

A Pilot Trial of Manlikang in Reducing Salt Intake and Blood Pressure Among Patients With Hypertension

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

July 30, 2018

Study Completion Date

July 30, 2018

Conditions
HypertensionHypertension With Abnormal Renal Function
Interventions
DIETARY_SUPPLEMENT

formula salt with very low sodium (Brand name: Manlikang)

hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.

Trial Locations (1)

400000

Maoer Shi community, Chongqing

All Listed Sponsors
lead

Peking University

OTHER

NCT03226327 - A Pilot Trial of Manlikang in Reducing Salt Intake and Blood Pressure Among Patients With Hypertension | Biotech Hunter | Biotech Hunter